MicroStar International has produced a report in which it claims Gigabyte is misleading consumers about its PCI-E 3.0 compliance. According to MSI only a board with the latest Gen3 Switch chips ...

SWAP-6 was an open-label pharmacokinetic and pharmacodynamic study that included 77 high-risk patients (mean age roughly 63 years; 22% women) who were undergoing PCI for stable CAD or NSTE ACS. They ...

According to the new label, acute stent thrombosis occurring within 4 hours of PCI has been observed at a higher rate in STEMI patients who are bivalirudin-treated (1.2%; 36/2889) compared with ...

SAN DIEGO — Patients with unprotected left main coronary artery stenosis who underwent PCI with a sirolimus-eluting stent or CABG had a similar rate of MACCE at 5-year follow-up. The prospective ...

PHILADELPHIA, April 24, 2025--PCI Pharma Services ("PCI") – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring ...

A new multicenter, single-arm, open-label study is the first to exclusively assess bleeding complications in patients undergoing high-risk percutaneous coronary interventions (PCI) with Impella ...

At one year after randomization, the primary endpoint had occurred in 25 of 1,005 patients (2.5%) in the OCT-guided PCI group and in 31 of 1,003 patients (3.1%) in the IVUS-guided PCI group (risk ...

PCR'05: Clopidogrel loading dose of 300 mg, 600 mg, or 900 mg -- which is most effective in inhibiting platelet activation in ACS patients undergoing PCI?

Long-term ticagrelor monotherapy after PCI lowered risk for bleeding compared with 1-year dual ... open-label superiority trial that enrolled more than 15,000 patients with ACS and stable ...

SAN FRANCISCO, CA (updated)— The 30-day risk of death or major bleeding fell significantly in ST-elevation MI (STEMI) patients treated with bivalirudin (Angiomax, the Medicines Company) compared ...